FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028776745> ?p ?o ?g. }

• W2028776745 endingPage "383" @default.
• W2028776745 startingPage "378" @default.
• W2028776745 abstract "Background Patients with small-cell lung cancer (SCLC) that progress after first-line chemotherapy have a poor prognosis and the evidence of a benefit from second-line (SL) chemotherapy is limited. Patients relapsing or progressing more than 90 days after completion of first-line treatment are considered platinum sensitive and may be rechallenged with platinum-based chemotherapy. Topotecan is approved as SL treatment independent of time to progression. This retrospective analysis evaluates the clinical outcomes of SCLC patients who received SL chemotherapy after platinum-etoposide chemotherapy. Patients and methods We retrospectively reviewed 161 patients who received SL chemotherapy for SCLC. Patients were divided into four subgroups by type of SL treatment: (1) platinum-based rechallenge; (2) anthracycline-based regimens; (3) topotecan; (4) other single agents. The endpoints were overall survival (OS), progression-free survival (PFS) and response rate (RR). Survival curves were plotted using the Kaplan–Meier method. The Cox proportional hazard model was used for multivariate analysis to investigate factors influencing survival. Results The median age was 63. There were 125 males and 36 females. Eastern Cooperative Oncology Group performance status (ECOG-PS) was 0, 1 and 2 in 12.5%, 62.5% and 25% of patients, respectively. Platinum sensitive/platinum resistant/platinum refractory/unknown = 121/29/3/8 patients. Median time to SL chemotherapy was 6.9 months. The median PFS from starting second-line treatment was 4.3 months and median OS was 5.8 months. The overall RR was 22.9%. There was a trend toward higher RR (34.5% vs 17.5%, p for trend: 0.06) and OS (9.2 months vs 5.8 months, p = 0.08) for patients with sensitive disease who were rechallenged with platinum-based chemotherapy. A multivariate analysis that adjusted for the time to SL treatment showed that a platinum-containing regimen achieves better RR, PFS and OS independently of the time to SL chemotherapy and that response to first-line treatment and PS at SL are the only independent prognostic factors. Conclusions The outcome for second-line therapy for SCLC was poor and benefit appeared to be limited to those patients with good PS and rechallenged with platinum-based chemotherapy. Platinum-based rechallenge should be considered as a standard comparator in future randomized controlled trials of SL chemotherapy." @default.
• W2028776745 created "2016-06-24" @default.
• W2028776745 creator A5001405340 @default.
• W2028776745 creator A5005515698 @default.
• W2028776745 creator A5010972450 @default.
• W2028776745 creator A5011073795 @default.
• W2028776745 creator A5011655337 @default.
• W2028776745 creator A5011883364 @default.
• W2028776745 creator A5014536795 @default.
• W2028776745 creator A5020493363 @default.
• W2028776745 creator A5021158045 @default.
• W2028776745 creator A5025637267 @default.
• W2028776745 creator A5025910383 @default.
• W2028776745 creator A5027018556 @default.
• W2028776745 creator A5029802418 @default.
• W2028776745 creator A5032078755 @default.
• W2028776745 creator A5035471408 @default.
• W2028776745 creator A5045629779 @default.
• W2028776745 creator A5049781283 @default.
• W2028776745 creator A5049996919 @default.
• W2028776745 creator A5068321284 @default.
• W2028776745 creator A5069095893 @default.
• W2028776745 creator A5089954905 @default.
• W2028776745 date "2011-06-01" @default.
• W2028776745 modified "2023-10-18" @default.
• W2028776745 title "Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis" @default.
• W2028776745 cites W1932169383 @default.
• W2028776745 cites W1942335159 @default.
• W2028776745 cites W1983141620 @default.
• W2028776745 cites W1983509220 @default.
• W2028776745 cites W2012368207 @default.
• W2028776745 cites W2015592470 @default.
• W2028776745 cites W2032076570 @default.
• W2028776745 cites W2063897709 @default.
• W2028776745 cites W2079713246 @default.
• W2028776745 cites W2080060706 @default.
• W2028776745 cites W2082203970 @default.
• W2028776745 cites W2105512851 @default.
• W2028776745 cites W2115465348 @default.
• W2028776745 cites W2129527916 @default.
• W2028776745 cites W2136930554 @default.
• W2028776745 cites W2138683149 @default.
• W2028776745 cites W2139163037 @default.
• W2028776745 cites W2142055223 @default.
• W2028776745 cites W2158127925 @default.
• W2028776745 cites W2167746331 @default.
• W2028776745 cites W2261287793 @default.
• W2028776745 cites W2323020638 @default.
• W2028776745 cites W2913381773 @default.
• W2028776745 cites W2595465817 @default.
• W2028776745 doi "https://doi.org/10.1016/j.lungcan.2010.09.009" @default.
• W2028776745 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20950888" @default.
• W2028776745 hasPublicationYear "2011" @default.
• W2028776745 type Work @default.
• W2028776745 sameAs 2028776745 @default.
• W2028776745 citedByCount "56" @default.
• W2028776745 countsByYear W20287767452012 @default.
• W2028776745 countsByYear W20287767452013 @default.
• W2028776745 countsByYear W20287767452014 @default.
• W2028776745 countsByYear W20287767452015 @default.
• W2028776745 countsByYear W20287767452016 @default.
• W2028776745 countsByYear W20287767452017 @default.
• W2028776745 countsByYear W20287767452018 @default.
• W2028776745 countsByYear W20287767452019 @default.
• W2028776745 countsByYear W20287767452020 @default.
• W2028776745 countsByYear W20287767452021 @default.
• W2028776745 countsByYear W20287767452022 @default.
• W2028776745 crossrefType "journal-article" @default.
• W2028776745 hasAuthorship W2028776745A5001405340 @default.
• W2028776745 hasAuthorship W2028776745A5005515698 @default.
• W2028776745 hasAuthorship W2028776745A5010972450 @default.
• W2028776745 hasAuthorship W2028776745A5011073795 @default.
• W2028776745 hasAuthorship W2028776745A5011655337 @default.
• W2028776745 hasAuthorship W2028776745A5011883364 @default.
• W2028776745 hasAuthorship W2028776745A5014536795 @default.
• W2028776745 hasAuthorship W2028776745A5020493363 @default.
• W2028776745 hasAuthorship W2028776745A5021158045 @default.
• W2028776745 hasAuthorship W2028776745A5025637267 @default.
• W2028776745 hasAuthorship W2028776745A5025910383 @default.
• W2028776745 hasAuthorship W2028776745A5027018556 @default.
• W2028776745 hasAuthorship W2028776745A5029802418 @default.
• W2028776745 hasAuthorship W2028776745A5032078755 @default.
• W2028776745 hasAuthorship W2028776745A5035471408 @default.
• W2028776745 hasAuthorship W2028776745A5045629779 @default.
• W2028776745 hasAuthorship W2028776745A5049781283 @default.
• W2028776745 hasAuthorship W2028776745A5049996919 @default.
• W2028776745 hasAuthorship W2028776745A5068321284 @default.
• W2028776745 hasAuthorship W2028776745A5069095893 @default.
• W2028776745 hasAuthorship W2028776745A5089954905 @default.
• W2028776745 hasConcept C121608353 @default.
• W2028776745 hasConcept C126322002 @default.
• W2028776745 hasConcept C141071460 @default.
• W2028776745 hasConcept C143998085 @default.
• W2028776745 hasConcept C167135981 @default.
• W2028776745 hasConcept C207103383 @default.
• W2028776745 hasConcept C2776256026 @default.
• W2028776745 hasConcept C2776694085 @default.
• W2028776745 hasConcept C2776802502 @default.

• next